SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
 To Contact Brower Piven Before The Lead Plaintiff Deadline - EconoTimes)
STEVENSON, Md., March 24, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of BioAmber Inc. (NYSE:BIOA) (BioAmber or the “Company”) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 and/or on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 17, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in BioAmber during the class period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 and the Securities Act of 1933 by virtue of the defendants’ failure to disclose during the Class Period, and in connection with its secondary public offering (“SPO”) of Company shares on or about January 23, 2017, that a large customer of BioAmber that was expected to purchase $2.8 million of succinic acid in Q4 2016 experienced a technical problem in its manufacturing facility and postponed the order to 2017.
According to the complaint, following a March 16, 2017 Company announcement of disappointing financial results and of the postponed order for succinic acid, the value of BioAmber shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in BioAmber during the class period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]
